The company has said that objective results from an independent radiology organization concluded the treatment resulted in an overall clinical benefit of 85%. Adventrx also reported longer than expected time to tumor progression (TTP), with no drug-related grade 3 or grade 4 gastrointestinal or hematological toxicities.
“The high level of activity and low toxicity of CoFactor suggests that this combination may prove useful as an initial treatment for metastatic colorectal cancer, especially among patients who would benefit from minimizing toxicity. These results give us added confidence as we proceed to our phase III pivotal study,” said Evan Levine, president of Adventrx.